Press Releases
Newest First
All Years
Press Release
November 6, 2026
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings
Press Release
November 5, 2026
EyePoint to Report Third Quarter 2026 Financial Results on November 12, 2026
Press Release
October 19, 2026
EyePoint Announces Topline Results from LUCIA, the Second Pivotal Phase 3 Clinical Trial of DURAVYU™ in Wet AMD
Press Release
October 19, 2026
EyePoint Announces Strategic Prioritization
Press Release
September 16, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press Release
September 2, 2026
EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meeting
Press Release
August 17, 2026
EyePoint Announces Topline Data from LUGANO, the First of Two Pivotal Phase 3 Clinical Trials for DURAVYU™ 2.7mg in Wet AMD
Press Release
August 14, 2026
EyePoint Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Press Release
August 5, 2026
EyePoint Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate Developments
Press Release
July 30, 2026
